John A. Glaspy
Impact in
- Hematology top 0.1%
- Erythropoietin and Anemia Treatment
- Iron Metabolism and Disorders
- Oncology top 0.05%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Neutropenia and Cancer Infections
Papers in
- Hematology 116
- Erythropoietin and Anemia Treatment 87
- Iron Metabolism and Disorders 43
- Oncology 163
- CAR-T cell therapy research 37
- Neutropenia and Cancer Infections 36
- Cancer Treatment and Pharmacology 31
- Cancer Immunotherapy and Biomarkers 21
- Co-authors
- Antoni RibasJames S. EconomouLisa H. ButterfieldWilliam H. McBrideVivian B. DissetteDilprit BaggaCarl K. HohSrinivasa T. Reddy
- Journals
- Journal of Clinical Oncology (48 papers)Blood (16 papers)Cancer (15 papers)Cancer Research (14 papers)Clinical Cancer Research (10 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
John A. Glaspy
331 papers receiving 20.6k citations
Hit Papers
Peers
Comparison fields: 5 of 164
- Hematology 4.8k
- Oncology 10.9k
- Immunology 5.3k
- Genetics 1.7k
- Biochemistry 871
Countries citing papers authored by John A. Glaspy
This map shows the geographic impact of John A. Glaspy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Glaspy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Glaspy more than expected).
Fields of papers citing papers by John A. Glaspy
This network shows the impact of papers produced by John A. Glaspy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Glaspy. The network helps show where John A. Glaspy may publish in the future.
Co-authors
The 25 scholars most cited alongside John A. Glaspy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2024 | 2 | |
| 3 | 2024 | 7 | |
| 4 | 2023 | 3 | |
| 5 | 2022 | 3 | |
| 6 | 2021 | 33 | |
| 7 | 2020 | 8 | |
| 8 | 2020 | 65 | |
| 9 | 2018 | 205 | |
| 10 | 2017 | 314 | |
| 11 | 2016 | 302 | |
| 12 | Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy Hit paper breakdown → | 2013 | 715 |
| 13 | 2011 | 120 | |
| 14 | Use of Erythropoiesis-stimulating Agents (ESAs) in Lung Cancer Patients: Study-level and Patient-level Meta-analyses of Safety Outcomes | 2010 | 1 |
| 15 | 2009 | 163 | |
| 16 | 2008 | 111 | |
| 17 | 2006 | 131 | |
| 18 | 1998 | 13 | |
| 19 | 1994 | 6 | |
| 20 | 1992 | 55 |
About John A. Glaspy
John A. Glaspy is a scholar working on Hematology, Oncology, Immunology, Genetics and Biochemistry, having authored 338 papers that have together received 21.4k indexed citations. Recurring topics across this work include Erythropoietin and Anemia Treatment (87 papers), Immunotherapy and Immune Responses (47 papers), Iron Metabolism and Disorders (43 papers), CAR-T cell therapy research (37 papers), Neutropenia and Cancer Infections (36 papers), Cancer Treatment and Pharmacology (31 papers), Hemoglobinopathies and Related Disorders (27 papers) and Cancer Immunotherapy and Biomarkers (21 papers). The work is most often cited by research in Hematology (4.8k citations), Oncology (10.9k citations), Immunology (5.3k citations), Genetics (1.7k citations) and Biochemistry (871 citations). John A. Glaspy has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Antoni Ribas, James S. Economou, Lisa H. Butterfield, William H. McBride, Vivian B. Dissette, Dilprit Bagga, Carl K. Hoh, Srinivasa T. Reddy, Jeffrey Crawford and Dennis J. Slamon. Their work appears in journals such as Journal of Clinical Oncology, Blood, Cancer, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.